Pages that link to "Q38944495"

The following pages link to The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma (Q38944495):

Displaying 31 items.

• The role of the ALK receptor in cancer biology (Q26738384) (← links)
• Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice (Q27853373) (← links)
• ERK5 and Cell Proliferation: Nuclear Localization Is What Matters (Q28078572) (← links)
• FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase (Q28118071) (← links)
• Research progress of neuroblastoma related gene variations (Q33566987) (← links)
• The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN (Q37305906) (← links)
• Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma (Q38294764) (← links)
• Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic (Q38540135) (← links)
• Oncogenic signaling of MEK5-ERK5. (Q39116456) (← links)
• Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma (Q41038822) (← links)
• Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. (Q41195708) (← links)
• Melatonin-mediated inhibition of Purkinje neuron P-type Ca²⁺ channels in vitro induces neuronal hyperexcitability through the phosphatidylinositol 3-kinase-dependent protein kinase C delta pathway (Q41364877) (← links)
• MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism (Q41610131) (← links)
• Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers (Q47134648) (← links)
• ALK Protein Expression is Related to Neuroblastoma Aggressiveness, But is Not Independent Prognostic Factor (Q47712911) (← links)
• ALK in Neuroblastoma: Biological and Therapeutic Implications. (Q52324760) (← links)
• ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. (Q52366358) (← links)
• MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function. (Q52584558) (← links)
• ALK pERKs up MYCN in neuroblastoma. (Q54312849) (← links)
• Impact of ERK5 on the Hallmarks of Cancer (Q64065870) (← links)
• Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides (Q64099587) (← links)
• Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation (Q64121696) (← links)
• Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib (Q89120437) (← links)
• Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy (Q89550782) (← links)
• Extracellular signal regulated kinase 5 promotes cell migration, invasion and lung metastasis in a FAK-dependent manner (Q90122397) (← links)
• ALK positively regulates MYCN activity through repression of HBP1 expression (Q90412302) (← links)
• DUSP5 expression associates with poor prognosis in human neuroblastoma (Q91256657) (← links)
• Targeting anaplastic lymphoma kinase in neuroblastoma (Q91895786) (← links)
• Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells (Q92095846) (← links)
• Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells (Q92110305) (← links)
• The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness (Q92643393) (← links)